JP2014523871A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523871A5
JP2014523871A5 JP2014514917A JP2014514917A JP2014523871A5 JP 2014523871 A5 JP2014523871 A5 JP 2014523871A5 JP 2014514917 A JP2014514917 A JP 2014514917A JP 2014514917 A JP2014514917 A JP 2014514917A JP 2014523871 A5 JP2014523871 A5 JP 2014523871A5
Authority
JP
Japan
Prior art keywords
composition
seq
functional
agent
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014514917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041804 external-priority patent/WO2012170977A1/en
Publication of JP2014523871A publication Critical patent/JP2014523871A/ja
Publication of JP2014523871A5 publication Critical patent/JP2014523871A5/ja
Pending legal-status Critical Current

Links

JP2014514917A 2011-06-10 2012-06-10 膵臓ベータ細胞増殖の調整 Pending JP2014523871A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495868P 2011-06-10 2011-06-10
US61/495,868 2011-06-10
US201261613856P 2012-03-21 2012-03-21
US61/613,856 2012-03-21
PCT/US2012/041804 WO2012170977A1 (en) 2011-06-10 2012-06-10 Modulation of pancreatic beta cell proliferation

Publications (2)

Publication Number Publication Date
JP2014523871A JP2014523871A (ja) 2014-09-18
JP2014523871A5 true JP2014523871A5 (enExample) 2015-06-18

Family

ID=47296512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514917A Pending JP2014523871A (ja) 2011-06-10 2012-06-10 膵臓ベータ細胞増殖の調整

Country Status (7)

Country Link
US (1) US20140303078A1 (enExample)
EP (1) EP2717924A4 (enExample)
JP (1) JP2014523871A (enExample)
CN (1) CN104039357A (enExample)
AU (1) AU2012267492A1 (enExample)
CA (1) CA2838824A1 (enExample)
WO (1) WO2012170977A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP2943512A4 (en) * 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
CA2904198A1 (en) * 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US9322037B2 (en) * 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN106536552A (zh) * 2014-03-12 2017-03-22 生物控股有限公司 能够拮抗胰岛淀粉样多肽(IAPP)诱导的β细胞损伤和葡萄糖耐量受损的新的化合物
CA2954082A1 (en) * 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
EP3749691A4 (en) 2017-11-10 2021-10-27 NGM Biopharmaceuticals, Inc. ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
US12508428B2 (en) 2023-01-26 2025-12-30 Medtronic, Inc. Respiratory-based cardiac remodeling pacing therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070055056A1 (en) * 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
JP2001512005A (ja) * 1997-08-01 2001-08-21 ジェンセット 内胚葉において発現する分泌タンパク質の5’est
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009511446A (ja) * 2005-10-05 2009-03-19 ノボ・ノルデイスク・エー/エス インスリンレセプターアンタゴニストと、関連した組成物、使用及び方法
CN101130768B (zh) * 2006-08-22 2010-05-12 复旦大学 核苷酸分子sr1b及其在制备抗糖尿病药物中的应用
NZ575804A (en) * 2006-09-13 2012-01-12 Univ Columbia Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Similar Documents

Publication Publication Date Title
Kang et al. Exercise-induced Musclin determines the fate of fibro-adipogenic progenitors to control muscle homeostasis
Chao et al. Knockdown of NPY expression in the dorsomedial hypothalamus promotes development of brown adipocytes and prevents diet-induced obesity
Zanotti et al. Decorin and biglycan expression is differentially altered in several muscular dystrophies
Dang et al. Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signalling pathway
Wang et al. Endostatin prevents dietary-induced obesity by inhibiting adipogenesis and angiogenesis
CN113769114A (zh) 癌症模型及相关方法
JP2015504299A5 (enExample)
JP7477448B2 (ja) Alkを調節する方法
Dai et al. Overexpression of SARAF ameliorates pressure overload–induced cardiac hypertrophy through suppressing STIM1-Orai1 in mice
CN114045335A (zh) circSpred1基因作为标志物在纤维化肝脏、肝癌的诊断和药物制备中的应用
Wu et al. Type 3 IP3 receptor: Its structure, functions, and related disease implications
Wang et al. The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy
AU2017248038A1 (en) Methods of modulating BCKDH
JP2020526554A (ja) 疼痛を管理するための方法
JP2011501672A5 (enExample)
JP2016520570A (ja) A型インフルエンザウイルス感染の治療又は予防に使用するためのpar−4アンタゴニスト
Day et al. NFAT expression in human osteoclasts
CA2988086C (en) An engineered ccl20 locked dimer polypeptide
Thomas et al. The roles of the PDZ-containing proteins bridge-1 and PDZD2 in the regulation of insulin production and pancreatic beta-cell mass
US11571462B2 (en) Engineered CCL20 locked dimer polypeptide
Higuchi et al. Direct Injection of Kit Ligand-2 Lentivirus Improves Cardiac Repair and Rescues Mice Post–myocardial Infarction
JP2020510611A (ja) Fam46aを調節する方法
JP2020515551A (ja) Ank1を調節する方法
Zhang et al. A conserved hormonal signalling–H2A. Z axis rapidly reorganizes 3D chromatin interactions in adipocyte thermogenesis
EP4013890A2 (en) Compositions and methods utilizing a novel human foxo3 isoform